Cis-aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signaling
Adeline Cezard, Déborah Bréa, Virginie Vasseur, Alan Wacquiez, Loïc Gonzalez, Ronan Le Goffic, Bruno Da Costa, Ambre Tinard, Delphine Fouquenet, Séverine Heumel, Arnaud Machelart, Eik Hoffmann, Priscille M Brodin, François Trottein, Cyrille Mathieu, , Mustapha Si‐Tahar
This study identifies cis-aconitate as a dual-action antiviral and anti-inflammatory agent that reduces influenza mortality in mice by targeting viral polymerase and ERK/AKT/NF-κB signaling.
EMBO Molecular Medicine · Feb 16, 2026Peer-reviewedImmunology